deltatrials
Terminated PHASE1 INTERVENTIONAL 1-arm NCT02818023

Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma

Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib for Therapy of Advanced Melanoma

Sponsor: Merck Sharp & Dohme LLC

Conditions Melanoma
Interventions Cobimetinib Pembrolizumab Vemurafenib
Updated 15 times since 2017 Last updated: Dec 10, 2021 Started: Jul 13, 2016 Primary completion: Jun 10, 2019 Completion: Apr 23, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Accrual to trial stopped due to high toxicity even at lowest dose of combination treatment. Patients on trial tolerating treatment at time of accrual closure still continued to receive treatment.

Other terminated trials from Merck Sharp & Dohme LLC

More terminations from Merck Sharp & Dohme LLC

Other Melanoma trials with similar outcome

Browse all Melanoma trials

This PHASE1 trial investigates Melanoma and is currently terminated or withdrawn. Merck Sharp & Dohme LLC leads this study, which shows 15 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Jul 2017 · 6 months · monthly snapshot~Jul 2017 – ~Oct 2017 · 3 months · monthly snapshot~Oct 2017 – ~May 2018 · 7 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Jan 2019 · 4 months · monthly snapshot~Jan 2019 – ~May 2019 · 4 months · monthly snapshot~May 2019 – ~Aug 2019 · 3 months · monthly snapshot~Aug 2019 – ~Aug 2020 · 12 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Jan 2022 · 12 months · monthly snapshot~Jan 2022 – ~Jun 2022 · 5 months · monthly snapshot~Jun 2022 – ~Jul 2024 · 25 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Jun 2022 — Jul 2024 [monthly]

    Terminated PHASE1

  4. Jan 2022 — Jun 2022 [monthly]

    Terminated PHASE1

    Status: Active Not Recruiting → Terminated

  5. Jan 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE1

▶ Show 10 earlier versions

  1. Aug 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  2. Aug 2019 — Aug 2020 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  3. May 2019 — Aug 2019 [monthly]

    Recruiting PHASE1

  4. Jan 2019 — May 2019 [monthly]

    Recruiting PHASE1

  5. Sep 2018 — Jan 2019 [monthly]

    Recruiting PHASE1

  6. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE1

  7. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

  8. Oct 2017 — May 2018 [monthly]

    Recruiting PHASE1

  9. Jul 2017 — Oct 2017 [monthly]

    Recruiting PHASE1

  10. Jan 2017 — Jul 2017 [monthly]

    Recruiting PHASE1

    First recorded

Jul 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
  • Yana Najjar
Data source: University of Pittsburgh

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations